Analyses of novel prognostic factors in neuroblastoma patients.
暂无分享,去创建一个
H. Mugishima | N. Nemoto | H. Shichino | M. Chin | Takashi Suzuki | Satoru Asami | Yoshikazu Yoshida | S. Ootsuka | T. Sasaki
[1] Lena Claesson-Welsh,et al. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.
[2] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[3] K. Møllgård,et al. Stem cell factor and c-Kit in human primordial germ cells and fetal ovaries , 2005, Molecular and Cellular Endocrinology.
[4] Rie Ito,et al. Significance of survivin mRNA expression in prognosis of neuroblastoma. , 2005, Biological & pharmaceutical bulletin.
[5] P. Span,et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. , 2004, Clinical chemistry.
[6] J. Berlin,et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.
[7] Haidong Wang,et al. The expression and significance of survivin mRNA in urinary bladder carcinomas , 2004, Journal of Cancer Research and Clinical Oncology.
[8] R. Parwaresch,et al. Expression of the c-kit receptor characterizes a subset of neuroblastomas with favorable prognosis , 2004, Oncogene.
[9] D. Kobayashi,et al. Survivin mRNA expression in patients with breast cancer. , 2002, Anticancer research.
[10] T. Sugimoto,et al. Prognostic discrimination among neuroblastomas according to ha‐ras/trk A gene expression , 1998, Cancer.
[11] P. Haber,et al. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] H. Enomoto,et al. Neuronal src and trk A protooncogene expression in neuroblastomas and patient prognosis , 1998, International journal of cancer.
[13] D. Altieri,et al. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.
[14] G. Krystal,et al. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. , 1996, Cancer research.
[15] B. Quesnel,et al. p53 Mutations Are Associated With Resistance to Chemotherapy and Short Survival in Hematologic Malignancies , 1994 .
[16] S. Kyo,et al. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. , 1994, Cancer research.
[17] J. Pelletier,et al. Absence of p53 gene mutations in primary neuroblastomas. , 1993, Cancer research.
[18] C. Dominici,et al. Coexpression of messenger RNA for TRK protooncogene and low affinity nerve growth factor receptor in neuroblastoma with favorable prognosis. , 1993, Cancer research.
[19] A. Cantor,et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. , 1993, The New England journal of medicine.
[20] D. Stram,et al. Lack of high-affinity nerve growth factor receptors in aggressive neuroblastomas. , 1993, Journal of the National Cancer Institute.
[21] K. Zsebo,et al. Effects of human stem cell factor (c-kit ligand) on proliferation of myeloid leukemia cells: heterogeneity in response and synergy with other hematopoietic growth factors. , 1992, Blood.
[22] H. Shirasawa,et al. Expression of N-myc and c-src protooncogenes correlating to the undifferentiated phenotype and prognosis of primary neuroblastomas. , 1991, Cancer research.
[23] David A. Williams,et al. Stem cell factor is encoded at the SI locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor , 1990, Cell.
[24] F. Collins,et al. Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.
[25] J. Minna,et al. p53: a frequent target for genetic abnormalities in lung cancer. , 1989, Science.
[26] T. Nagatsu. The human tyrosine hydroxylase gene , 1989, Cellular and Molecular Neurobiology.
[27] A. Levine,et al. The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.
[28] A. Ullrich,et al. Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.
[29] J. Mallet,et al. A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics , 1987, Nature.
[30] P. Chomczyński,et al. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. , 1987, Analytical biochemistry.
[31] E. Frenkel,et al. Characterization of human neuroblastoma cell lines established before and after therapy. , 1986, Journal of the National Cancer Institute.
[32] H. Sather,et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. , 1985, The New England journal of medicine.
[33] T. Sawada,et al. MASS SCREENING FOR NEUROBLASTOMA IN INFANTS IN JAPAN Interim Report of a Mass Screening Study Group , 1984, The Lancet.
[34] H. Varmus,et al. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. , 1984, Science.
[35] A. Donfrancesco,et al. Clinical and molecular evidence for c-kit receptor as a therapeutic target in neuroblastic tumors. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[36] G. Brodeur. Molecular basis for heterogeneity in human neuroblastomas. , 1995, European journal of cancer.